Te Ahumairangi Investment Management Ltd Raises Position in DaVita Inc. $DVA

Te Ahumairangi Investment Management Ltd boosted its position in shares of DaVita Inc. (NYSE:DVA) by 15.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 78,973 shares of the company’s stock after acquiring an additional 10,507 shares during the quarter. DaVita comprises about 1.6% of Te Ahumairangi Investment Management Ltd’s portfolio, making the stock its 16th largest position. Te Ahumairangi Investment Management Ltd owned about 0.11% of DaVita worth $8,972,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Empowered Funds LLC grew its stake in DaVita by 422.3% during the 4th quarter. Empowered Funds LLC now owns 22,966 shares of the company’s stock valued at $2,609,000 after purchasing an additional 18,569 shares during the last quarter. Inceptionr LLC purchased a new stake in DaVita during the 4th quarter valued at about $679,000. Zions Bancorporation National Association UT grew its stake in DaVita by 533.1% during the 4th quarter. Zions Bancorporation National Association UT now owns 1,032 shares of the company’s stock valued at $117,000 after purchasing an additional 869 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in DaVita during the 4th quarter worth about $504,000. Finally, Cerity Partners LLC grew its position in DaVita by 8.4% during the 4th quarter. Cerity Partners LLC now owns 2,818 shares of the company’s stock worth $320,000 after purchasing an additional 219 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on DVA. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. UBS Group raised their target price on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Barclays raised their target price on DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Truist Financial raised their target price on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Finally, Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, DaVita presently has an average rating of “Hold” and an average target price of $199.17.

Insider Transactions at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

DaVita Trading Up 2.6%

DVA stock opened at $203.72 on Friday. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $205.42. The stock has a market cap of $13.08 billion, a price-to-earnings ratio of 18.90, a PEG ratio of 0.65 and a beta of 0.91. The business’s 50-day moving average is $174.98 and its 200 day moving average is $145.65.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same period in the previous year, the firm posted $2.00 EPS. DaVita’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts forecast that DaVita Inc. will post 15.07 EPS for the current fiscal year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.